Previous 10 | Next 10 |
Athersys press release (NASDAQ:ATHX): Q1 GAAP EPS of -$0.09 in-line. Revenue of $2.91M beats by $1.53M. “Receiving FDA approval to use the bioreactor manufactured product gives us confidence as we further scale our third-generation bioreactor manufacturing process to be able to produce...
Management to host conference call following announcement of Phase 2/3 TREASURE data in May Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athe...
Athersys (NASDAQ:ATHX) is scheduled to announce Q1 earnings results on Friday, May 6th, before market open. The consensus EPS Estimate is -$0.09 (+30.8% Y/Y) and the consensus Revenue Estimate is $1.38M (+Infinity% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 ...
ABR,ACMR,AEE,AES,ASIX,ATHX,AXL,BBU,BCC,BEP,BKI,BWEN,CI,CLMT,CNK,CNTY,CPLP,DISH,DKNG,EAF,ECOM,ENB,EOG,ESNT,FLR,FWONA,FYBR,GLP,GT,GTN,HYZN,OTCPK:ICAGY,ICPT,IEP,IMGN,ING,INTT,LSXMK,MITT,NRG,OCGN,OFS,OIIM,PRLB,PTR,QRTEA,ROAD,RUTH,SII,SPB,SR,SSP,TAC,TSAT,TTSH,TU,UA,UAA,VIVO,VST For Seeking Alpha's...
Company has been focused on developing a viable treatment for stroke for nearly 20 years. Article will discuss chances for success in treating stroke with Phase 3 results to be reported in Japan this month. Company could offer colossal returns for high-risk tolerant investors. ...
Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, and Ivor Macleod, Chief Financial Officer, will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on Wednesday, May 11, 2022 at 4:00 p.m. PT in Las ...
Quarterly Conference Call to be Held Following Announcement of Phase 2/3 TREASURE Data in May Athersys, Inc. (Nasdaq: ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT. In anticipation of the announce...
Penny stocks are well-known for their potential to produce huge gains for traders. These high-risk, high-reward assets have polarized the retail market. You either love them or try to avoid them at all costs. High levels of volatility have opened doors for crushing drops in price and some o...
On 04/11/2022, Athersys shares spiked after a long downward slide, soon they were back on the skids. Athersys' big dollar late-stage therapeutic candidates are highly attractive. Athersys' uncertain financial future will challenge its shareholder mettle to the core. For furt...
Athersys Inc. (NASDAQ:ATHX) traded at a new 52-week high today of $4.49. This new high was reached on above average trading volume as 148.6 million shares traded hands, while the average 30-day volume is approximately 1.8 million shares. In the past 52 weeks, Athersys Inc. share prices a...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...